News about "chronic lymphocytic leukaemia"

AstraZeneca's Calquence-Venetoclax Regimen Approved in US as First All-Oral Fixed-Duration Therapy for CLL

AstraZeneca's Calquence-Venetoclax Regimen Approved in US as First All-Oral Fixed-Duration Therapy for CLL

FDA clears 14-month, chemotherapy-free combination for first-line treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma, backed by positive Phase III AMPLIFY trial data.

Chronic Lymphocytic Leukaemia | 23/02/2026 | By News Bureau

Kernal Biologics receives USD 48 Million from ARPA-H

Kernal Biologics receives USD 48 Million from ARPA-H

The funding received by Kernal Biologics from ARPA-H is to develop lower cost in vivo CAR T-cell therapies for hematological cancers.

Chronic Lymphocytic Leukaemia | 09/10/2025 | By Dineshwori 154


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members